Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone
| Autor: | Swerdlow , Anthony, Cooke , Rosie, Albertsson-Wikland , Kerstin, Borgström , Birgit, Butler , Gary, Cianfarani , Stefano, Clayton , Peter, Coste , Joël, Deodati , Annalisa, Ecosse , Emmanuel, Gausche , Ruth, Giacomozzi , Claudio, Kiess , Wieland, Hokken-Koelega , Anita, Kuehni , Claudia, Landier , Fabienne, Maes , Marc, Mullis , Primus-E, Pfaffle , Roland, Sävendahl , Lars, Sommer , Grit, Thomas , Muriel, Tollerfield , Sally, Zandwijken , Gladys, Carel , Jean-Claude |
|---|---|
| Přispěvatelé: | UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Unité d'endocrinologie pédiatrique, Institute of Cancer Research - ICR [London, U.K.], Sahlgrenska Academy at University of Gothenburg [Göteborg], Karolinska Institutet [Stockholm], Institute of Child Health [London], University College of London [London] (UCL), University College London Hospitals (UCLH), IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Royal Manchester Children's Hospital, University of Manchester [Manchester], Unité d’Epidémiologie et de Biostatistiques [APHP Cochin-Broca-Hôtel Dieu], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Universität Leipzig [Leipzig], Erasmus University Medical Center [Rotterdam] (Erasmus MC), Sophia Children's Hospital, Institute of Social and Preventive Medicine [Bern] (ISPM), Universität Bern [Bern], Centre de Référence des Maladies Endocriniennes Rares de la Croissance [APHP Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service d'endocrinologie diabétologie pédiatrique [CHU Debré], AP-HP Hôpital universitaire Robert-Debré [Paris], Université Paris Diderot - Paris 7 (UPD7), Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques Hopital Robert Debre, Institut National de la Santé et de la Recherche Médicale (INSERM), Cliniques universitaires St Luc [Bruxelles], Inselspital Bern, Belgian Study Group for Pediatric Endocrinology (BSGPE), Universitair Ziekenhuis Brussel, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), University College of London [London] ( UCL ), University College London Hospitals ( UCLH ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Erasmus Medical Center / Dutch Growth Research Foundation, Erasmus University Medical Center [Rotterdam], Institute of Social and Preventive Medicine [Bern] ( ISPM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 ( UPD7 ), Université Paris Diderot - Paris 7 ( UPD7 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Belgian Study Group for Pediatric Endocrinology ( BSGPE ), Pediatrics |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
MESH : Risk MESH : Child Preschool Cohort Studies MESH: Cause of Death MESH: Recombinant Proteins MESH : Child Cause of Death Neoplasms MESH: Child MESH: Human Growth Hormone MESH : Female MESH: Neoplasms MESH: Incidence Child MESH: Cohort Studies Growth Disorders Cancer MESH: Risk Human Growth Hormone Incidence MESH: Infant Newborn Cohort MESH : Infant [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie MESH: Follow-Up Studies MESH: Growth Disorders MESH: Infant MESH : Incidence Recombinant Proteins Europe MESH: Young Adult Child Preschool Female Risk Adolescent MESH : Recombinant Proteins MESH : Male MESH : Europe MESH : Young Adult MESH : Cohort Studies 610 Medicine & health MESH : Infant Newborn Young Adult SDG 3 - Good Health and Well-being 360 Social problems & social services MESH : Adolescent Humans MESH : Growth Disorders MESH : Human Growth Hormone Mortality Growth hormone MESH : Cause of Death Settore MED/38 - Pediatria Generale e Specialistica MESH: Adolescent Original Paper MESH: Humans MESH : Humans MESH: Child Preschool Infant Newborn Infant MESH : Follow-Up Studies MESH : Neoplasms MESH: Male [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie MESH: Europe MESH: Female Follow-Up Studies |
| Zdroj: | Hormone Research in Paediatrics : from developmental endocrinology to clinical research, Vol. 84, no.3, p. 172-183 (2015) Swerdlow, Anthony J; Cooke, Rosie; Albertsson-Wikland, Kerstin; Borgström, Birgit; Butler, Gary; Cianfarani, Stefano; Clayton, Peter; Coste, Joël; Deodati, Annalisa; Ecosse, Emmanuel; Gausche, Ruth; Giacomozzi, Claudio; Kiess, Wieland; Hokken-Koelega, Anita C S; Kuehni, Claudia E; Landier, Fabienne; Maes, Marc; Mullis, Primus-E; Pfaffle, Roland; Sävendahl, Lars; ... (2015). Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone. Hormone research in paediatrics, 84(3), pp. 172-183. Karger 10.1159/000435856 Hormone Research in Paediatrics Hormone Research in Paediatrics, Karger, 2015, 84 (3), pp.172-183. ⟨10.1159/000435856⟩ Hormone Research in Pædiatrics Hormone Research in Paediatrics, Karger, 2015, 84 (3), pp.172-183. 〈10.1159/000435856〉 Hormone Research in Paediatrics, 84, 172-183. S. Karger AG |
| ISSN: | 1663-2818 1663-2826 |
| DOI: | 10.1159/000435856 |
| Popis: | International audience; BACKGROUND:The long-term safety of growth hormone treatment is uncertain. Raised risks of death and certain cancers have been reported inconsistently, based on limited data or short-term follow-up by pharmaceutical companies.PATIENTS AND METHODS:The SAGhE (Safety and Appropriateness of Growth Hormone Treatments in Europe) study assembled cohorts of patients treated in childhood with recombinant human growth hormone (r-hGH) in 8 European countries since the first use of this treatment in 1984 and followed them for cause-specific mortality and cancer incidence. Expected rates were obtained from national and local general population data. The cohort consisted of 24,232 patients, most commonly treated for isolated growth failure (53%), Turner syndrome (13%) and growth hormone deficiency linked to neoplasia (12%). This paper describes in detail the study design, methods and data collection and discusses the strengths, biases and weaknesses consequent on this.CONCLUSION:The SAGhE cohort is the largest and longest follow-up cohort study of growth hormone-treated patients with follow-up and analysis independent of industry. It forms a major resource for investigating cancer and mortality risks in r-hGH patients. The interpretation of SAGhE results, however, will need to take account of the methods of cohort assembly and follow-up in each country. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|